Curemark Announces New Patent Covering Treatment Of Drug And Alcohol Addiction

RYE, N.Y., Nov. 27, 2012 /PRNewswire/ -- Curemark announced today that it has been granted patent #8,318,158 for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction.  This is the second in a series of patent grants for this indication.  The newest patent is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same."

"Individuals with drug and alcohol addiction have impairments in protein breakdown. The ability to identify those individuals and subsequently treat them is a big step forward in the management of their addictions," states Dr. Joan Fallon, founder and CEO of Curemark.  "In the past, addiction has been examined in the silo of the disease with little consideration of the contributory or resultant symptoms."

Dr. Matthew Heil, Curemark's Chief Scientific Officer, adds, "The National Institute on Alcohol Abuse and Alcoholism continues to examine the effects of alcohol on the body. We believe that our findings with respect to those affected with alcohol addiction may shed light upon the etiology of this debilitating disease. Curemark's understanding of the effects of impairments in protein breakdown on the brain will lead the way into a new paradigm for treatment of multiple disease states."

In December 2011, Curemark reported that its Phase III double-blind randomized placebo-controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints.  The trial compared CM-AT to placebo in children with autism 3-8 years of age. Top line results demonstrate a statistically significant effect of CM-AT over placebo on both the core and non-core symptoms of autism, the company said.

The FDA has placed CM-AT into the Fast Track program which facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company announced in December, 2011, that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints.  To learn more about our innovative science, visit

Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC